Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:NKTR NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$25.55+1.3%$25.98$16.90▼$39.71$406.07M1.08241,499 shs142,148 shsNKTRNektar Therapeutics$70.72+2.0%$65.37$21.02▼$109.00$2.39B1.131.18 million shs835,968 shsSLGLSol-Gel Technologies$81.96+1.8%$74.88$10.48▼$97.97$230.30M1.1235,715 shs24,517 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%-4.70%+5.32%-8.32%+39.39%NKTRNektar Therapeutics0.00%+3.60%+14.01%-22.86%+182.88%SLGLSol-Gel Technologies0.00%-1.49%+12.78%+9.53%+724.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$25.55+1.3%$25.98$16.90▼$39.71$406.07M1.08241,499 shs142,148 shsNKTRNektar Therapeutics$70.72+2.0%$65.37$21.02▼$109.00$2.39B1.131.18 million shs835,968 shsSLGLSol-Gel Technologies$81.96+1.8%$74.88$10.48▼$97.97$230.30M1.1235,715 shs24,517 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%-4.70%+5.32%-8.32%+39.39%NKTRNektar Therapeutics0.00%+3.60%+14.01%-22.86%+182.88%SLGLSol-Gel Technologies0.00%-1.49%+12.78%+9.53%+724.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.57Moderate Buy$44.0072.21% UpsideNKTRNektar Therapeutics 2.75Moderate Buy$150.00112.10% UpsideSLGLSol-Gel Technologies 2.67Moderate Buy$197.50140.97% UpsideCurrent Analyst Ratings BreakdownLatest ASMB, SLGL, and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026NKTRNektar Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$153.007/20/2026SLGLSol-Gel Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.007/17/2026ASMBAssembly Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/15/2026ASMBAssembly Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$40.00 ➝ $45.006/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)6/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/28/2026ASMBAssembly Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.005/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/15/2026SLGLSol-Gel Technologies Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$72.30M5.62N/AN/A$13.04 per share1.96NKTRNektar Therapeutics$55.23M43.27N/AN/A$4.41 per share16.04SLGLSol-Gel Technologies$19.39M11.88N/AN/A$8.19 per share10.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$6.12M-$0.11N/AN/AN/A-8.98%-4.21%-3.14%8/5/2026 (Estimated)NKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)Latest ASMB, SLGL, and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2026Q2 2026SLGLSol-Gel Technologies-$2.31N/AN/AN/A$0.15 millionN/A8/6/2026Q2 2026NKTRNektar Therapeutics-$1.94N/AN/AN/A$10.43 millionN/A8/5/2026Q2 2026ASMBAssembly Biosciences-$0.70N/AN/AN/A$8.60 millionN/A5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/7/2026Q1 2026ASMBAssembly Biosciences-$0.65-$0.54+$0.11-$0.54$9.27 million$8.21 million5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A6.656.65NKTRNektar TherapeuticsN/A10.2110.21SLGLSol-Gel TechnologiesN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%NKTRNektar Therapeutics75.88%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences3.50%NKTRNektar Therapeutics2.50%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences10015.89 million15.34 millionOptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataASMB, SLGL, and NKTR HeadlinesRecent News About These CompaniesAffinity Asset Advisors LLC Purchases Shares of 35,000 Sol-Gel Technologies Ltd. $SLGLJuly 25 at 3:12 AM | marketbeat.comHC Wainwright Brokers Boost Earnings Estimates for SLGLJuly 24 at 1:13 AM | americanbankingnews.comSol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | BenzingaJuly 23 at 10:50 PM | benzinga.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by AnalystsJuly 23 at 3:15 AM | americanbankingnews.comHC Wainwright Issues Positive Estimate for SLGL EarningsJuly 22, 2026 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Sol-Gel Technologies (NASDAQ:SLGL)July 20, 2026 | marketbeat.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by BrokeragesJuly 18, 2026 | marketbeat.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 SharesJuly 11, 2026 | insidertrades.comOpaleye Management Inc. Acquires 229 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJuly 10, 2026 | marketbeat.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,107.00 in StockJuly 10, 2026 | marketbeat.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in StockJuly 3, 2026 | insidertrades.comSol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho SecuritiesJune 26, 2026 | theglobeandmail.comSol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million OfferingMay 30, 2026 | theglobeandmail.comSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue EstimatesMay 28, 2026 | zacks.comSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 28, 2026 | globenewswire.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of StockMay 15, 2026 | insidertrades.comSol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary SharesMarch 23, 2026 | quiverquant.comQSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingMarch 23, 2026 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2026 | zacks.comSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025March 19, 2026 | globenewswire.comThis Under-the-Radar Stock Has Surged 1,300% Over the Past YearMarch 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASMB, SLGL, and NKTR Company DescriptionsAssembly Biosciences NASDAQ:ASMB$25.55 +0.33 (+1.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$25.54 -0.02 (-0.06%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Nektar Therapeutics NASDAQ:NKTR$70.72 +1.36 (+1.96%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$71.19 +0.47 (+0.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Sol-Gel Technologies NASDAQ:SLGL$81.96 +1.41 (+1.75%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$82.66 +0.70 (+0.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
